SCHEMBL2572378

SCHEMBL2572378

C=CCNCCc1ccccc1F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TAAR1 Q96RJ0 4/20 0.55
▸ MPO P05164 4/20 0.54
▸ HPGD P15428 1/20 0.51
▸ CYP1A2 P05177 1/20 0.49
▸ GLA P06280 1/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ CYP2D6 P10635 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ GFER P55789 1/20 0.48
▸ EPHX2 P34913 1/20 0.48
▸ AOC3 Q16853 1/20 0.43
▸ CHRM2 P08172 1/20 0.43
▸ CHRM1 P11229 1/20 0.43
▸ CHRM3 P20309 1/20 0.43
▸ CNR1 P21554 1/20 0.42
▸ THRB P10828 1/20 0.41
▸ SLC6A4 P31645 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14292004 0.81 MPO (0.49) TAAR1MPOHPGDCYP1A2GLA
Hydrochloric Acid SCHEMBL7368184 0.81 TAAR1 (0.67) TAAR1MPOHPGDCYP1A2GLA
SCHEMBL11200694 0.79 ADRB2 (0.39) MPOKMT2ASLC6A4
SCHEMBL13574203 0.79 TAAR1 (0.55) TAAR1HPGDCYP1A2GLACYP3A4
SCHEMBL10316496 0.76 HPGD (0.53) HPGDCYP1A2CYP2C9CYP2C19MEN1
SCHEMBL17033966 0.76 TAAR1 (0.66) TAAR1MPOHPGDCYP1A2GLA
SCHEMBL7563209 0.75 TAAR1 (0.56) TAAR1MPOHPGDAOC3
SCHEMBL2859013 0.74 TAAR1 (0.58) TAAR1MPOHPGDCYP1A2GLA
SCHEMBL172293 0.74 TAAR1 (0.63) TAAR1MPOHPGDCYP1A2GLA
SCHEMBL11567426 0.73 MAPT (0.54) HPGDCYP1A2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1626961-B1 NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME KOREA RES INST OF BIOSCIENCE (KR) 2011-11-02 — — EP disclosed
US-7846963-B2 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2010-12-07 — — US disclosed
US-20100286207-A1 Novel 2-Oxo-Heterocyclic Compounds And The Pharmaceutical Compositions Comprising The Same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2010-11-11 — — US disclosed
US-7723376-B2 2-oxo-heterocyclic compounds and pharmaceutical compositions KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2010-05-25 — — US disclosed
EP-1626961-A4 NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME KOREA RES INST OF BIOSCIENCE (KR) 2008-07-16 — — EP disclosed
US-20070167486-A1 Novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2007-07-19 — — US disclosed
US-20060173043-A1 Use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2006-08-03 — — US disclosed
EP-1663201-A1 A USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME Korea Research Institute of Bioscience and Biotechnology (KR) 2006-06-07 — — EP disclosed
EP-1626961-A1 NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME Korea Research Institute of Bioscience and Biotechnology (KR) 2006-02-22 — — EP disclosed
WO-2005004861-A1 A USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2005-01-20 — — WO disclosed
WO-2004101523-A1 NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2004-11-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286207-A1 Novel 2-Oxo-Heterocyclic Compounds And The Pharmaceutical Compositions Comprising The Same NOD2, BMP2, NOD1 TAAR1 4108/4885MPO 543/4885HPGD 1829/4885
US-20070167486-A1 Novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same NOD2, NOD1, BMP2 TAAR1 4170/4885MPO 541/4885HPGD 2069/4885
US-20060173043-A1 Use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same MALT1, BRCA1, MCL1 TAAR1 4833/4885MPO 292/4885HPGD 278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback